Healthcare Business Recap: Vivus and Jazz Pharmaceuticals Target Prices
Jazz Pharmaceuticals’ (NASDAQ:JAZZ) price target is lifted by Jefferies from $56 to $64, as the analyst expects that the firm can surpass its own guidance with its reconfigured sales structure. Jazz’ earnings per share estimates were also increased for fiscal year 2012 and fiscal year 2013 by $0.04 and $0.73, respectively
Cowen calls for a $40 trading price on shares for Vivus (NASDAQ:VVUS) if Qnexa receives final FDA approval to become the first weight-loss drug since 1999 with such a mandate. Shares rise accordingly.
Industry-watcher John McCamant calls Pharmacyclics (NASDAQ:PCYC) ‘one of the most exciting names in biotech’, pointing out the company’s B-cell lymphoma drug that is in phase 2. Pharmacyclics also obtained a deal with a unit of Johnson & Johnson that includes a $150 million upfront payment and a 50/50 profit/loss split worldwide. This recommendation raised shares Wednesday.
Bio-Reference Laboratories (NASDAQ:BRLI) beat its fiscal first quarter estimates in a Wednesday report that showed its revenue soaring 23 percent year-to-year. The clinical-testing company’s patient count has jumped and its share of complex, non-routine testing services continues to increase on double digit sales growth.
Earnings Report: Allos Therapeutics Inc. Fourth Quarter Earnings Sneak Peek.
To contact the reporter on this story: Mark Lawson at firstname.lastname@example.org
To contact the editor responsible for this story: Damien Hoffman at email@example.com